FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
0:00
3:30
Listen to a soundcast of the November 17, 2021 FDA approval of Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Fler avsnitt från "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Missa inte ett avsnitt av “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” och prenumerera på det i GetPodcast-appen.